Ng George K 4

What Happened George K. Ng, CEO of Processa Pharmaceuticals, acquired 2,136 shares of PCSA on 2026-03-31 at $2.54 per share, for a total outlay of approximately $5,415. The Form 4 lists the transaction as a purchase (code P), an open-market or private purchase reported on 2026-04-01. This was a direct purchase by the CEO (a bullish signal in that purchases can indicate confidence), though the dollar amount is modest.

Key Details

• Transaction date and price: 2026-03-31 — 2,136 shares at $2.54 each.
• Total value: ~ $5,415.
• Filing date / accession: Form 4 filed 2026-04-01 (Accession No. 0000897069-26-000750).
• Shares owned after transaction: Not provided in the information supplied.
• Notable footnotes: No 10b5‑1 plan, tax-withholding, or other footnotes were indicated in the provided data.
• Timeliness: Filing appears timely (reported the next day); not flagged as late.

Context This was a straightforward cash purchase (purchase code P), not an option exercise, award, or gift. While insider buys are often more informative than sales, this particular purchase is small in dollar value, so it should be weighed accordingly alongside other insider activity and company fundamentals.